Here’s why Allkem shares are getting multiple broker upgrades

A little boy holds his fingers to his head posing as a bull.A little boy holds his fingers to his head posing as a bull.

The Allkem Ltd (ASX: AKE) share price is inching lower today, trading at $13.05 at the time of writing.

Zooming out, Allkem shares have lunged 29% higher in the last month and 135% in the last 12 months.

Swimming in a sea of green, the company has just scored itself a number of broker upgrades. Particularly given its ambition to become one of the world’s biggest lithium suppliers.

TradingView Chart

Why are analysts bullish on Allkem shares?

Analysts have put themselves behind Allkem in sequential fashion these past few months. In that time the company has released a number of lithium updates.

“Allkem has the lofty goal of becoming the world’s third biggest supplier of lithium chemicals and snaring 10 per cent of the market by 2030,” The Australian reports.

Not only that, but Allkem’s seemingly diversified offering positions it well to capitalise on emerging trends in the energy space, JP Morgan analysts say.

“Allkem (formerly Orocobre) holds a suite of both operating and development lithium projects and is well placed to capitalise on the growing electrification thematic,” it said in a recent note.

It operates across all three key lithium chemicals, with the Olaroz lithium brine JV in Argentina, the Mt Cattlin spodumene mine in Western Australia, and has the Naraha hydroxide conversion facility in Japan ramping up.

The growth pipeline is full, with Stage 2 at Olaroz more than doubling production and potential for Stage 3, while the greenfield Sal de Vida brine project in Argentina and James Bay Spodumene project in Canada offer additional medium-term growth.

The broker retains its overweight rating on the Allkem share price. JP Morgan has an $18.50 per share valuation on a blend of these catalysts for price change.

“With the backdrop of continuing lithium demand and pricing strength and AKE’s substantial growth pipeline, we remain overweight,” it concluded.

‘Ready to roar’

Meanwhile, analysts at Bell Potter believe the company’s growth engine is well fuelled and primed to roar in 2022. They are keeping it on the bullish side as well.

Assigning a buy call and an $18.05 price target on Allkem shares, Bell Potter said, “[t]he company’s growth pipeline supports this strategy [the goal outlined above] and is fully funded, even using a price outlook which is conservative compared to spot markets.”

With this commentary in mind, it appears brokers like Allkem’s balance sheet and fundamentals. Of course, that’s on a backdrop of an extensive spot rally in commodities.

The consensus price target on Allkem shares is $14.87, according to Bloomberg data. Further, 81.8% of analysts recommend buying right now. That’s up from 30% exactly one year ago.

The post Here’s why Allkem shares are getting multiple broker upgrades appeared first on The Motley Fool Australia.

Should you invest $1,000 in Allkem right now?

Before you consider Allkem, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Allkem wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/wZulp5M

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *